David R Tortolani

This inventor holds 18 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Bristol-Myers Squibb Compnay, Institute of Organic Chemistry and Biochemistry, Rega Stichting, V.z.w.. Active years: 1996-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David R Tortolani. Retrieved from https://idiyas.com/inventor/david-r-tortolani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 5.9

ph-index = 8

Forward Citations = 507(Granted Patents)

Location History:

Princeton, NJ (US) (1996 - 1998)
Meriden, CT (US) (1996 - 1998)
Skillman, NJ (US) (2001 - 2023)

Company Filing History:

16 out of 3,742

Bristol-Myers Squibb Compnay

patents

2 out of 50

Institute of Organic Chemistry and Biochemistry

patents

2 out of 21

Rega Stichting, V.z.w.

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12473290 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2025-11-18),

2. 11739098 - Substituted indole compounds (2023-08-29),

3. 11306092 - Amino indole compounds useful as TLR inhibitors (2022-04-19),

4. 10660877 - Pyridyl substituted indole compounds (2020-05-26),

5. 10196387 - Carbazole compounds useful as bromodomain inhibitors (2019-02-05),

6. 10053454 - Carbazole compounds useful as bromodomain inhibitors (2018-08-21),

7. 9492460 - Carbazole compounds useful as bromodomain inhibitors (2016-11-15),

8. 7968577 - Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof (2011-06-28),

9. 7723336 - Fused heterocyclic compounds useful as kinase modulators (2010-05-25),

10. 6995181 - Modulators of the glucocorticoid receptor and method (2006-02-07),

11. 6225324 - Antidepressant heterocyclic compounds (2001-05-01),

12. 5849923 - Heterocyclic-substituted naphthalenyl retinobenzoic acid derivatives (1998-12-15),

13. 5792756 - Prodrugs of phosphonates (1998-08-11),

14. 5663159 - Prodrugs of phosphonates (1997-09-02),

15. 5648385 - Retinoid-like compounds (1997-07-15),

Title: **David R. Tortolani: Innovator in Pharmaceutical Chemistry**

Introduction

David R. Tortolani, based in Skillman, NJ, is a prominent inventor with an impressive portfolio of 17 patents. His work primarily focuses on pharmaceutical innovations, particularly in the realm of compounds that target inflammatory and autoimmune diseases. With a strong background in organic chemistry, Tortolani has made significant contributions to the field through his inventions.

Latest Patents

Among his latest inventions are several patented compounds characterized as substituted indole compounds. These inventions include compounds of Formula (I) or their salts, which serve as inhibitors of signaling through Toll-like receptors 7, 8, and 9. His research highlights the potential of these compounds in treating inflammatory and autoimmune diseases. Similarly, Tortolani has developed amino indole compounds, also outlined in his patents, that share therapeutic properties related to Toll-like receptor inhibition.

Career Highlights

Tortolani has had an influential career, working with notable organizations such as Bristol-Myers Squibb Company and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences. His experiences in these respected institutions have honed his expertise in pharmaceutical chemistry and paved the way for his substantial contributions to drug development.

Collaborations

Throughout his career, David R. Tortolani has collaborated with several distinguished colleagues, including John E. Starrett, Jr. and Muzammil M. Mansuri. These partnerships have further enriched his research and expanded the potential applications of his innovative compounds in the pharmaceutical industry.

Conclusion

David R. Tortolani's dedication to innovation in pharmaceutical chemistry has led to noteworthy advancements in treatments for inflammatory and autoimmune diseases. With a robust patent portfolio and valuable collaborations, he continues to pave the way for future discoveries in the field. As a seasoned inventor, Tortolani exemplifies the spirit of innovation that drives progress in healthcare and pharmaceutical research.

Profile summary based on public USPTO records.